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See related research by Duffy and Parmar, http://breast-cancer-research.com/content/15/3/R41By analysing a theoretical cohort, Duffy and Parmar [1]
find 0% overdiagnosis when screening for breast cancer
in the UK. The fundamental assumption in their calcula-
tion is that the average lead time is 40 months, and this
estimate relies on a method proposed by Walter and
Day [2] for calculating lead time.
Clinical lead time and statistical lead time are two fun-
damentally different concepts. Clinical lead time is the
time diagnosis of a clinical relevant disease is moved by
screening [3]. Statistical lead time is the time diagnosis
is being moved by screening when all tumours grow and
there are no competing causes of death [2]. It is a theor-
etical concept including both clinical cancers that are
detected earlier and overdiagnosed tumours. Statistical
lead time for breast cancer varies between 2 and 7 years
(depending on the level of overdiagnosis), while the clin-
ical lead time is about 1 year [3]. If you adjust the inci-
dence increase when screening for statistical lead time, it
will always give estimates of overdiagnosis close to zero
because you subtract all clinical cancers that are diag-
nosed earlier as well as all overdiagnosed cancers from
the incidence increase during screening [3].
In my opinion, the authors incorrectly assume that lead
time is 40 months and postulate an 86% reduction in breastCorrespondence: per-henrik.zahl@fhi.no




© BioMed Central Ltd.2014cancer rate between the first two screening rounds [1]. The
literature on estimates of breast cancer rates between two
screening rounds (so-called interval cancer rate), which re-
flects the clinical lead time, reports that the decline was
48% based on a small data set [4] and close to 0% in a large
British data set [5]. Tables two and three in [1] do not rep-
resent real breast cancer data. It is a constructed data set
that, by definition, yields 0% overdiagnosis.
Ten years after screening they postulate a 7% reduc-
tion in incidence. However, after 20 years with overdiag-
nosis and overtreatment, a small reduction in breast
cancer incidence is expected simply because many
healthy women have lost their breast and are using anti-
oestrogens, both of which reduce the numbers of
women at risk of breast cancer. The reduction is not the
effect of early diagnosis but of overtreatment or, at best,
what could be called prophylactic treatment.
Finally in Table four in [1], the authors argue that the
level of overdiagnosis adjusted for statistical lead time
varies with length of screening as well as the length of
follow-up after last screening (because the denominator
varies). This is actually an argument for not using this
method. Overdiagnosis adjusted for clinical lead time is
insensitive to these effects [3].Dr Zahl claims that we estimate 0% overdiagnosis in
breast cancer screening. In fact, our paper does not esti-
mate overdiagnosis at all. It calculates what we would
expect to happen to breast cancer incidence from lead
time alone and demonstrates that if we were to estimateoverdiagnosis from incidence alone, we would need long
follow-up to deal with this lead time effect.
Dr Zahl’s main point is that what he calls ‘statistical’
estimates of lead time are exaggerated, leading to under-
estimation of overdiagnosis, due to inclusion of over-
diagnosed cancers in the estimation. However, we have
observed estimates of lead time similar to the value used in
our paper that do not use overdiagnosed cancers in the
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http://breast-cancer-research.com/content/16/3/404estimation, either by explicitly dividing the screen-detected
cancers in the estimation [6,7] or by use of interval cancer
rates alone [8], which are not screen-detected and therefore
cannot include overdiagnosed cases. A more careful reading
of the literature is suggested. It is also worth noting that
others estimate rather longer lead times than that assumed
in our paper [9].
Our estimated lead time is based on observation in
randomised trials of screening. Dr Zahl’s preferred method
of estimation, which he refers to as ‘clinical’ lead time,
seems to have a large number of statistical manipulations
and assumptions that we find difficult to verify [3].
Our postulated population was one with 100% attend-
ance at every screen in a 2-yearly programme, as we
noted in our paper, and so of course has different num-
bers to those in the 3-yearly UK programme with 70 to
75% attendance. Our conclusion still stands: to estimate
screening-induced overdiagnosis from incidence rates
alone requires long follow-up to be reliable, and overdi-
agnosis has been exaggerated in the past due to insuffi-
cient duration of observation.
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